Acurx announces positive top-line ibezapolstat phase 2 efficacy results with 96% clinical cure rate in patients with c. difficile infection

In a total of 26 ibezapolstat-treated patients in phases 2a and 2b, the clinical cure rate is 96% meets protocol primary objective of assessing the primary efficacy endpoint of the clinical cure rate after 10 days of oral treatment ibezapolstat was well tolerated; no drug-related serious adverse events further analyses forthcoming regarding secondary and exploratory endpoints, including sustained clinical cure data, extended clinical cure data up to 94 days and comparative effects on gut microbiome preparation underway for end-of-phase 2 fda meeting and advancement to phase 3 ibezapolstat has previously received fda qualified infectious disease product and fast-track designationmanagement will be available for q&a on november 14, 2023 earnings call https://www.acurxpharma.com/news-media/press-releases/detail/65/acurx-pharmaceuticals-to-discuss-third-quarter-2023 staten island, n.y. , nov. 2, 2023 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) ("acurx" or the "company"), a clinical stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced efficacy results from the phase 2 clinical trial (phase 2a segment and phase 2b segment) of ibezapolstat for the treatment of c.
ACXP Ratings Summary
ACXP Quant Ranking